GMA 107
Alternative Names: GMA-107Latest Information Update: 28 Dec 2024
At a glance
- Originator Gmax Biopharm
- Class Hepatoprotectants; Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in China (Parenteral)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Obesity in China (Parenteral)
- 03 Nov 2020 GMA 107 is available for licensing as of 03 Nov 2020. http://www.gmaxbiopharm.com/job.html